RPC Pharma Ltd 13D and 13G filings for Akari Therapeutics, Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-10-20 5:00 pm Purchase | 2023-10-06 | 13D | Akari Therapeutics, Plc AKTX | RPC Pharma Ltd | 2,537,089,900 21.800% | 2,422,344,655 (+2111.06%) | Filing |
| 2023-04-14 4:06 pm Purchase | 2023-03-31 | 13D | Akari Therapeutics, Plc AKTX | RPC Pharma Ltd | 114,745,245 22.700% | 68,037,935 (+145.67%) | Filing |
| 2022-01-14 4:18 pm Purchase | 2021-12-29 | 13D | Akari Therapeutics, Plc AKTX | RPC Pharma Ltd | 46,707,310 18.000% | 2,022,975 (+4.53%) | Filing |
| 2021-10-18 5:06 pm Purchase | 2021-07-07 | 13D | Akari Therapeutics, Plc AKTX | RPC Pharma Ltd | 44,684,335 18.800% | 3,060,480 (+7.35%) | Filing |
| 2020-03-30 4:52 pm Purchase | 2019-07-03 | 13D | Akari Therapeutics, Plc AKTX | RPC Pharma Ltd | 41,623,855 28.800% | 2,506,575 (+6.41%) | Filing |